医学
凝血病
血管性血友病因子
外科
止血
药代动力学
因子IX
内科学
重症监护医学
血小板
作者
Annette von Drygalski,Pratima Chowdary,Roshni Kulkarni,Sophie Susen,Barbara A. Konkle,J. Oldenburg,Davide Matino,Robert Klamroth,Angela C. Weyand,Víctor Jiménez‐Yuste,Keiji Nogami,Stacey Poloskey,Bent Winding,Annemieke Willemze,Karin Knobe
标识
DOI:10.1056/nejmoa2209226
摘要
Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor–imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with severe hemophilia A are unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI